Loading...

Loading...

Poor Sleep Tied to Higher Dementia Risk, Study Finds
By Aura Moreno - Mon, 09/22/2025 - 09:18
Chronic insomnia may raise dementia risk by 40% and accelerate brain aging, highlighting sleep’s role in health and productivity.

Partnership Content

Cluster Automotriz Nuevo Leon
https://mexicobusiness.news/tag/cognitive-decline
More Health
Personalized Care, Supplements, Public Health: The Week in Health
By Sofía Garduño - Thu, 08/28/2025 - 13:29
Mexico’s health sector sees growth in supplements, investments, and policy, while it focuses on risks like air pollution.

Air Pollution Raises Heart, Cognitive Risks
By Eliza Galeana - Tue, 08/26/2025 - 18:16
Research reveals that prolonged exposure to air pollution increases the risk of heart attacks and accelerates cognitive decline.

Hearing Loss as a Hidden Contributor to Dementia
By Aura Moreno - Mon, 05/26/2025 - 09:26
Hearing loss increases dementia risk. Early detection and hearing aids can reduce cognitive decline in millions of Mexicans.
Shingles Vaccine Linked to Lower Dementia Risk
By Sofía Garduño - Wed, 04/02/2025 - 17:00
The shingles vaccine may lower dementia risk, offering potential health benefits beyond preventing the virus, a new study finds.
Study Links Long-Term NSAID Use to Lower Dementia Risk
By Sofía Garduño - Wed, 03/19/2025 - 15:28
A study suggests that the long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce dementia risk by lowering inflammation.
Study Reveals Two-Phase Model of Alzheimer’s Disease Progression
By MBN Staff - Thu, 10/17/2024 - 10:19
A study reveals brain damage occurs before Alzheimer’s symptoms emerge, supporting a two-phase model of disease progression.

IMSS Highlights Early Alzheimer’s Diagnosis for Better Outcomes
By Sofía Garduño - Wed, 10/09/2024 - 09:30
IMSS highlights the need for early Alzheimer’s detection amid rising memory loss in older adults.
Study Shows Leqembi Cuts Cognitive Decline by 31%
By MBN Staff - Wed, 07/31/2024 - 17:22
Leqembi's data shows a 31% reduction in cognitive decline, with no new safety issues, contrasting with Lilly’s Kisunla in cost and approach.